#survodutide
LightNews LightNews
biologist077.bsky.social
i'm genuinely surprised by these survodutide results for people with obesity and type 2 diabetes. a phase iii trial with 755 adults showed up to 13.1% weight loss and their hba1c (a blood sugar marker) fell up to 1.21%. hitting two hormone systems seems really effective.
Boehringer Ingelheim's Survodutide Achieves Up to 13.1% Weight Loss and Significant Glycemic Control
Results from the Phase III SYNCHRONIZE-2 trial show that survodutide, a glucagon/GLP-1 receptor dual agonist, led to significant weight reduction and improved blood sugar control in adults with obesit
www.boehringer-ingelheim.com
October 3, 2026 at 8:00 AM
reuters.com
Zealand Pharma slides as concerns over patients quitting survodutide trials resurface reut.rs/4hz72bN
Zealand Pharma slides as concerns over patients quitting survodutide trials resurface
Nearly one in five patients quit Zealand Pharma's late-stage survodutide trial due to ​gastrointestinal side effects caused by the ‌obesity drug, data released on Thursday showed, again raising investor concerns over the high dropout rates.
reut.rs
October 1, 2026 at 11:45 AM
wsj.com
EXCLUSIVE: Survodutide shows potential to predominantly target visceral fat, its Chief Executive Shashank Deshpande said in an interview. on.wsj.com/4cAYa4e
Boehringer Ingelheim’s Obesity Drug Helps Lose Fat Rather Than Muscle, Late-Stage Trial Shows
EXCLUSIVE: Survodutide shows potential to predominantly target visceral fat, its Chief Executive Shashank Deshpande said in an interview.
on.wsj.com
April 28, 2026 at 6:20 AM
wsj.com
Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said. on.wsj.com/3RT8zR2
Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot’s Side Effects
Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said.
on.wsj.com
June 8, 2026 at 11:25 AM
nejm.org
In a phase 3 trial involving adults with obesity but without diabetes, the glucagon receptor–GLP-1 receptor dual agonist survodutide led to significantly greater reductions in body weight than placebo. Full SYNCHRONIZE-1 trial results: https://nej.md/4x7Tafs

#ADASciSessions
Bar chart from the article "Survodutide Once Weekly for the Treatment of Adults with Obesity" published in the New England Journal of Medicine. It shows overall change in body weight: survodutide 3.6 mg at –12.2%, survodutide 6.0 mg at –13.0%, and placebo at –5.4%. The American Diabetes Association’s 2026 Scientific Sessions are mentioned.
June 7, 2026 at 6:35 PM
biologist077.bsky.social
Good Phase III data on survodutide for obesity & type 2 diabetes. A 13.1% body weight drop over 76 weeks—that's like 26 lbs on a 200 lb person vs just 6 lbs with placebo. Makes you think about the future of managing these diseases.
October 3, 2026 at 8:00 PM
biologist077.bsky.social
Just saw survodutide's Phase III data: people with obesity & type 2 diabetes lost up to 13.1% body weight & cut HbA1c (average blood sugar) by 1.21%. Big improvements like these can make a real difference in managing both conditions.
Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongsid
In a Phase III trial (SYNCHRONIZE-2), the experimental drug survodutide, a dual glucagon/GLP-1 receptor agonist, led to substantial weight reduction and improved blood sugar control in adults with obe
www.biospace.com
October 2, 2026 at 2:01 PM
nejm.org
In a phase 3, double-blind, placebo-controlled trial involving adults with obesity and type 2 diabetes, the investigational glucagon receptor–GLP-1 receptor dual agonist survodutide led to significant weight reduction. Full SYNCHRONIZE-2 trial results: https://nej.md/4yrHEMu

#EASD2026
A bar chart showing the percent change in body weight from baseline to week 76, derived from an analysis-of-covariance model, for the treatment-regimen estimand, which incorporates the effects of any early discontinuation of survodutide or placebo, the use of protocol-prohibited obesity medications, and the effects of a prolonged dose-escalation period.
October 1, 2026 at 7:35 AM
scinews.bsky.social
Survodutide reduces fibrosis and inflammation in people with metabolic liver disease.
November 21, 2024 at 5:33 PM
natureportfolio.nature.com
A phase 3 trial reported in Nature Medicine shows weekly subcutaneous injections of survodutide, a glucagon receptor/GLP-1R dual agonist, lowered liver fat content and body weight in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD). #medsky 🧪
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial - Nature Medicine
As presented at the American Diabetes Association Meeting, in this phase 3 trial, weekly subcutaneous injections of survodutide, a glucagon receptor/GLP-1R dual agonist, lowered liver fat content and body weight compared to placebo in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD).
go.nature.com
June 13, 2026 at 10:40 PM
rnflex.bsky.social
This is LONG read but I promise it's worth it. Survodutide= liver fat busting drug of future
CagriSema= ???? Role still undefined!

But finally some solid proof that Amylin(and especially calcitonin) isn't really the drug target we want for diabetics unless you just want raw weight loss
ADA Conference 2026: CagriSema & Survodutide
A tale of dual agonists, glucagon or amylin, who wins the insulin sensitivity race?
the-incretins.beehiiv.com
June 19, 2026 at 4:42 PM
danieljdrucker.bsky.social
Clinically meaningful #weightloss data for Mazdutide in China, expanding options for GLP-1 medicines. Will survodutide be the first glucagon-GLP-1 medicine to report a CV outcomes trial?
May 25, 2025 at 10:36 PM
reuters.com
Zealand Pharma shares drop 20% as obesity drug side effects raise concerns reut.rs/49MI59X
Zealand Pharma shares drop 20% as obesity drug side effects raise concerns
Zealand ​Pharma's shares ‌fell more than ​20% ​in early trade ⁠on ​Monday after ​trial data showed its ​obesity ​drug survodutide had ‌worse ⁠side effects and higher ​patient ​dropout ⁠rates than ​rival ​treatments.
reut.rs
June 8, 2026 at 7:45 AM
danieljdrucker.bsky.social
Dissecting the importance of the murine GCGR vs the GLP-1R for the CNS and #weightloss actions of survodutide @MolMetab www.sciencedirect.com/science/arti...
February 3, 2026 at 11:06 AM
agibus.bsky.social
#DragiWebdo n°536 : dépistage CMV (reco HAS), recos ESC (insuffisance cardiaque, coroscanner, maladie rénale chronique), atorvastatine/sujet âgé, fibrillation auriculaire, e-cigarette, survodutide, suivi en MG

www.medicalement-geek.com/2026/09/drag...
Dragi Webdo n°536 : dépistage CMV (reco HAS), recos ESC (insuffisance cardiaque, coroscanner, maladie rénale chronique), atorvastatine/sujet âgé, fibrillation auriculaire, e-cigarette, survodutide, su...
Dragi Webdo n°536 : dépistage CMV (reco HAS), recos ESC (insuffisance cardiaque, coroscanner, maladie rénale chronique), atorvastatine, FA, MG
www.medicalement-geek.com
September 7, 2026 at 10:27 PM
nejm.org
SYNCHRONIZE-1: GLP-1 receptor agonists have transformed obesity care, yet unmet treatment needs persist. The glucagon receptor–GLP-1 receptor dual agonist survodutide showed efficacy for weight loss in a phase 2 trial. Research is summarized in a new Quick Take video. https://nej.md/3SKaqbo
A silhouette of a patient with obesity stands on a medical scale, with an illustration of a medication pen labeled "Survodutide" above. Beside them, a calendar shows the month with several dates checkmarked.
August 26, 2026 at 7:00 PM
enclai.net
Survodutide reduces weight by 9.8% in adults with obesity and type 2 diabetes.
Survodutide reduces weight by 9.8% in adults with obesity and type 2 diabetes
Survodutide reduces weight by 9.8% in adults with obesity and type 2 diabetes. In adults with obesity and type 2 diabetes, survodutide at a weekly dose of 3.6 mg or 6.0 mg resulted in significantly greater weight reduction than placebo. Randomised trial, NEJM, 1 Oct 2026.
enclai.net
October 2, 2026 at 11:30 AM
trending-finance.bsky.social
Survodutide stumbles; Zealand shares slide #econsky
October 1, 2026 at 12:01 PM
jama.com
#GLP1 medicines now address weight loss and other health conditions through innovative formulations and expanded indications, highlighting key questions about their efficacy and safety.

ja.ma/4og9wNX
JAMA article 'New Molecules and Indications for GLP-1 Medicines'. Diagrams show Semaglutide, Tirzepatide for approved medications, Retatrutide, Survodutide for emerging medications. Approved indications listed: obesity, type 2 diabetes, sleep apnea, etc.
October 14, 2025 at 4:00 PM
rnflex.bsky.social
Just thinking about the fact when I can prescribe glucagon agonist drugs (retatrutide, survodutide) I'm just waiting for the patient complaint of bad breath, tasting metal etc because the drugs force you into mild ketosis even if you eat carbs.

Me to them: Don't worry that's just fat burning off!
June 19, 2026 at 10:28 PM
nejm.org
In a phase 3 trial involving adults with obesity but without diabetes, the glucagon receptor–GLP-1 receptor dual agonist survodutide led to significantly greater reductions in body weight than placebo. Full SYNCHRONIZE-1 trial results and Research Summary: https://nej.md/4x7Tafs
This image contains an excerpt from the Research Summary "Survodutide Once Weekly for the Treatment of Adults with Obesity" published in the New England Journal of Medicine. It includes participant details with 725 adults, an average age of 47 years, and a gender distribution of 59% women and 41% men. The graphic explains that survodutide is an investigational glucagon receptor-GLP-1 receptor dual agonist. Below are three treatment groups: survodutide (up to 3.6 mg once weekly) (N=241), survodutide (up to 6.0 mg once weekly) (N-242), and placebo (N=242). A prompt to read the full Research Summary at NEJM.org sits at the bottom.
September 1, 2026 at 7:00 PM
midgardfinance.com
Obesity Phase 3: efficacy vs tolerability.

Tirz + CagriSema: best quadrant.

Retatrutide: top efficacy, mid dropouts.

Survodutide: alone in high-dropout / mid-efficacy.

🇩🇰 #$ZEAL 🇩🇰 #$NOVO #$NVO 🇺🇸 #$LLY

#GLP1 #Obesity #BoehringerIngelheim #Survodutide #SYNCHRONIZE1
Scatter plot titled "Obesity Phase 3 landscape: weight loss vs treatment dropouts" with subtitle "Survodutide sits alone in the high-dropout / mid-efficacy quadrant". X-axis: discontinuation due to adverse events (%). Y-axis: weight loss at primary endpoint (%). Six drugs plotted: Survodutide 6 mg SYNCHRONIZE-1 at 19% disc / -16.6% weight (red, outlier), Retatrutide 12 mg TRIUMPH-1 at 11.3% / -28.3%, Tirzepatide 15 mg SURMOUNT-1 at 6.2% / -22.5% (green, best-in-class), CagriSema 2.4/2.4 REDEFINE-1 at 6.0% / -22.7% (green), Orforglipron 36 mg ATTAIN-1 at 10.3% / -11%, Semaglutide 7.2 mg STEP-UP at 3.3% / -20.7%. Quadrant labels show high-efficacy / low-dropouts is best (top-left), high-efficacy / high-dropouts is mid (top-right), low-efficacy / high-dropouts is worst (bottom-right where survodutide sits).
June 8, 2026 at 12:47 PM
medpagetoday.com
An investigational dual GIP/GLP-1 agonist achieved modest weight loss in adults with type 2 diabetes and obesity, the phase III SYNCHRONIZE-2 trial showed, but tolerability remains a concern. @easdnews.bsky.social #EASD2026
https://www.medpagetoday.com/meetingcoverage/easd/123234
Novel GIP/GLP-1 Yields Uneven Findings in Diabetes Patients With Obesity
Phase III trial of survodutide showed modest weight loss and high discontinuation rates
www.medpagetoday.com
October 2, 2026 at 1:44 AM
boehringerglobal.bsky.social
#NEWS: Phase III trial data for people living with #obesity, overweight & #T2D were presented today at @easdnews.bsky.social

These results will help us understand how survodutide can provide weight loss benefits whilst improving blood sugar levels.

👉 go.boehringer.com/SBqTr

#LifeForward #EASD2026
October 1, 2026 at 7:36 AM
midgardfinance.com
💉 #obesity #EASD2026

🇩🇪 Boehringer's #survodutide, from 🇩🇰 Zealand, in obesity with type 2 diabetes. Phase 3, NEJM:

Weight, all randomised: -9.8% vs -3.9% placebo
On treatment: -13.1%
Stopped for side effects: 26% vs 9%. Four rivals: 6-11%

midgardfinance.com/obesity/drugs/survodutide/

#$ZEAL
Scatter chart of five obesity drugs in their phase 3 trials in adults with obesity and type 2 diabetes, one point per drug at its top dose. Across: the share of patients who stopped the drug because of side effects. Down: average weight change counting all randomised patients. Semaglutide 7.2 mg (STEP UP T2D, 72 weeks): 6 per cent stopped, weight -13.2 per cent. Retatrutide 12 mg (TRIUMPH-2, 80 weeks): 7 per cent stopped, weight -18.8 per cent. CagriSema 2.4/2.4 mg (REDEFINE 2, 68 weeks): 8 per cent stopped, weight -13.7 per cent. Orforglipron 36 mg (ATTAIN-2, 72 weeks): 11 per cent stopped, weight -9.6 per cent. Survodutide 6 mg (SYNCHRONIZE-2, 76 weeks): 26 per cent stopped, weight -9.8 per cent. Four of the points sit between 6 and 11 per cent stopping; survodutide is alone on the right at 26 per cent, with about the same weight loss as the oral drug orforglipron. Survodutide's trial was published in the New England Journal of Medicine on 1 October 2026. These are separate trials with different participants and lengths, not a head-to-head comparison. Tirzepatide is not shown because its trial's published summary gives no comparable figure for stopping.
October 1, 2026 at 12:30 PM